Phone: 1-800-226-2379

Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects with Advanced Sarcoma (HEROS)

Diseases

Sarcomas; refractory HER2-positive sarcoma or metastatic HER2-positive osteosarcoma, not treatable by surgical resection

Description

HER2 is a growth factor receptor that is expressed in many kinds of cancers including some sarcomas. Tumors that express HER2 tend to be more aggressive, so we have developed a chimeric antigen receptor (CAR) to target HER2. In our phase I trial for patients with relapsed or refractory sarcomas (NCT00902044), HER2 CAR T cells are generated from the patient’s own immune cells and are delivered back to the patient in combination with lymphodepletion chemotherapy. The goal of this trial is to determine the safety of HER2 CAR T cells in combination with lymphodepletion chemotherapy and to evaluate whether addition of the chemotherapy improves the anti-tumor response.

Eligibility Criteria

Ages Eligible for Study: Children, Adult

Sexes Eligible for Study: All

Other inclusion and exclusion criteria as listed on clinicaltrials.gov.

Contact

Nabil M. Ahmed, MD   
Principal Investigator
832-824-4611    
nmamed@txch.org

Meenakshi Hegde, MD   
832-824-4840    
mghegde@txch.org